Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD

Journal of the American Society of Nephrology

Volumn 22, Issue 2, 2011, Pages 387-395

  Schlieper, Georg ^a   Westenfeld, Ralf ^b   Krüger, Thilo ^a   Cranenburg, Ellen C ^c   Magdeleyns, Elke J ^c   Brandenburg, Vincent M ^a   Djuric, Zivka ^d   Damjanovic, Tatjana ^d   Ketteler, Markus ^e   Vermeer, Cees ^c   Dimkovic, Nada ^d   Floege, Jürgen ^a   Schurgers, Leon J ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d ZVEZDARA UNIVERSITY MEDICAL CENTER   (Serbia)

^e KLINIKUM COBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DECARBOXYPROTHROMBIN; FARNOQUINONE; MATRIX GLA PROTEIN; OSTEOCALCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD VESSEL CALCIFICATION; CARBOXYLATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; KAPLAN MEIER METHOD; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; SURVIVAL; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 79551662074     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010040339     Document Type: Article

References (32)

1. US Renal Data System: USRDS 1998 annual data report. Am J Kidney Dis 32: 69-80, 1998
2. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
3. Schlieper G, Westenfeld R, Brandenburg V, Ketteler M: Inhibitors of calcification in blood and urine. Semin Dial 20: 113-121, 2007
4. Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112: 357-366, 2003
5. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361: 827-833, 2003
6. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386: 78-81, 1997
7. Wajih N, Borras T, Xue W, Hutson SM, Wallin R: Processing and transport of matrix gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular smooth muscle cells: Evidence for an uptake mechanism for serum fetuin. J Biol Chem 279: 43052-43060, 2004
8. Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated locally: Different roles of two gla-containing proteins. J Cell Biol 165: 625-630, 2004
9. Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, van Diest R, Appels A, Reutelingsperger CP, Cleutjens JP, Vermeer C: Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 25: 1629-1633, 2005
10. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM: Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118: 1748-1757, 2008
11. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M, Negrao AP: A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 19: 1480-1488, 2004
12. Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic N, Schurgers L, Kruger T, Westenfeld R, Ackermann D, Haselhuhn A, Dimkovic S, Ketteler M, Floege J, Dimkovic N: Risk factors for cardiovascular calcifications in non-diabetic Caucasian haemodialysis patients. Kidney Blood Press Res 32: 161-168, 2009
13. Rennenberg RJ, Schurgers LJ, Vermeer C, Scholte JB, Houben AJ, de Leeuw PW, Kroon AA: Renal handling of matrix Gla-protein in humans with moderate to severe hypertension. Hypertens Res 31: 1745-1751, 2008
14. Hermans MM, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, Gladziwa U, Rensma PL, Leunissen KM, Schurgers LJ: Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif 25: 395-401, 2007
15. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA: The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. Clin J Am Soc Nephrol 5: 568-575, 2010
16. Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, Vermeer C, Schurgers LJ: Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med 268: 483-492, 2010
17. Pilkey RM, Morton AR, Boffa MB, Noordhof C, Day AG, Su Y, Miller LM, Koschinsky ML, Booth SL: Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 49: 432-439, 2007
18. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL: Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol 5: 590-597, 2010
19. Chan KE, Lazarus JM, Thadhani R, Hakim RM: Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20: 2223-2233, 2009
20. Kruger T, Floege J: Coumarin use in dialysis patients with atrial fibrillation: More harm than benefit? Nephrol Dial Transplant 24: 3284-3285, 2009
21. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial. J Am Soc Nephrol 13: 2331-2337, 2002
22. Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18: 1400-1407, 1998
23. Koos R, Mahnken AH, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger JE, Kuhl HP: Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 96: 747-749, 2005
24. Shea MK, O'Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, Price PA, Williamson MK, Booth SL: Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 89: 1799-1807, 2009
25. Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van dM, I, Hofman A, Witteman JC: Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J Nutr 134: 3100-3105, 2004
26. Gast GC, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, Witteman JC, Grobbee DE, Peeters PH, van der Schouw YT: A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis 19: 504-510, 2009
27. Schlieper G, Kruger T, Djuric Z, Damjanovic T, Markovic N, Schurgers LJ, Brandenburg VM, Westenfeld R, Dimkovic S, Ketteler M, Grootendorst DC, Dekker FW, Floege J, Dimkovic N: Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int 74: 1582-1587, 2008
28. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol 14: 159-168, 2003
29. Bellasi A, Ferramosca E, Muntner P, Ratti C, Wildman RP, Block GA, Raggi P: Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 70: 1623-1628, 2006
30. Grosley BM, Hirschauer C, Chambrette B, Bezeaud A, Amiral J: Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma. J Lab Clin Med 127: 553-564, 1996
31. Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM, Bouwman FG, Kwaijtaal M, Brandenburg VM, Ketteler M, Schurgers LJ: The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 45: 427-436, 2008
32. Cranenburg EC, Brandenburg VM, Vermeer C, Stenger M, Muhlenbruch G, Mahnken AH, Gladziwa U, Ketteler M, Schurgers LJ: Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 101: 359-366, 2009